证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-077 江苏恒瑞医药股份有限公司 第九届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 5 月 12 日 江苏恒瑞医药股份有限公司（以下简称"公司"）第九届董事会第十六次会 议于 2025 年 5 月 12 日以通讯方式召开。本次会议应到董事 9 人，实到董事 9 人。会议召开符合《公司法》《公司章程》的规定。公司全体董事认真审议并通 过《关于确定公司 H 股全球发售（包括香港公开发售及国际发售）及在香港联 交所上市的议案》 董事会同意关于公司 H 股全球发售及在香港联交所上市的相关安排，包括 但不限于：（1）刊发符合相关法律法规要求的招股说明书及其他相关文件；（2） 处理 H 股发行程序及相关事项；（3）授权相关人士按相关决议处理与本次发行 上市有关的具体事务。 赞成：9 票 反对：0 票 弃权：0 票 特此公告。 江苏恒瑞医药股份有限公司董事会 ...

截至5月12日收盘，创新药概念下跌0.60%，位居概念板块跌幅榜前列，板块内，迈威生物、百济神 州、泽璟制药等跌幅居前，股价上涨的有76只，涨幅居前的有通化金马、新开源、*ST赛隆等，分别上 涨6.84%、6.25%、5.01%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中船系 | 6.55 | 重组蛋白 | -0.94 | | 成飞概念 | 5.77 | 代糖概念 | -0.82 | | 军工信息化 | 4.28 | 转基因 | -0.77 | | 同花顺果指数 | 4.17 | 创新药 | -0.60 | | 国产航母 | 3.73 | 粮食概念 | -0.60 | | 军民融合 | 3.69 | 玉米 | -0.59 | | 航空发动机 | 3.42 | 大豆 | -0.45 | | 人形机器人 | 3.20 | 农业种植 | -0.31 | | 减速器 | 3.20 | 生物质能发电 | -0.28 | | 军工 | 3.15 | 减肥药 | -0.24 | 资金面上看，今日创新药概念板块获主 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7624.71 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.46% in the past month, 3.56% in the past three months, and 2.43% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI 300 Index, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.5%), WuXi AppTec (15.98%), Pian Zai Huang (6.77%), Yunnan Baiyao (5.51%), Kelun Pharmaceutical (4.73%), New Horizon (3.69%), East China Pharmaceutical (3.68%), Shanghai Raist (3.39%), Changchun High-tech (3.33%), and Fosun Pharma (3.23%) [1] - The market segment of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.75% and the Shenzhen Stock Exchange accounts for 36.25% [2] - In terms of industry composition, chemical drugs account for 43.27%, pharmaceutical and biotechnology services for 21.11%, traditional Chinese medicine for 19.35%, and biological drugs for 16.27% [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are fixed until the next scheduled adjustment unless a temporary adjustment is required [2] - Special events affecting sample companies may lead to changes in industry classification, and companies that are delisted will be removed from the index [2]

Investment Rating - The investment rating for the biopharmaceutical industry is "Positive" (maintained) [2] Core Insights - The report highlights the aggressive nature of small cell lung cancer (SCLC), with extensive stage SCLC accounting for approximately 75% of cases, which often rely on systemic treatment and have a poor prognosis [6][21] - The first-line treatment for extensive stage SCLC primarily involves PD-1/PD-L1 immunotherapy combined with doublet chemotherapy, while there are limited approved drugs for later-line treatments, indicating a significant unmet clinical need [24][30] - The report identifies three key areas of focus for research and development in the SCLC field: Antibody-Drug Conjugates (ADC), DLL3 T-cell engagers (TCE), and next-generation immune-oncology (IO) therapies [30][34] Summary by Sections 1. SCLC Overview - SCLC accounts for about 15%-20% of all lung cancer cases, with a high incidence of early metastasis [18][19] - The majority of SCLC cases are extensive stage, which has a poor prognosis and relies heavily on systemic therapies [21][22] 2. Treatment Landscape - The standard treatment for extensive stage SCLC has been established as a combination of chemotherapy and PD-1/PD-L1 immunotherapy, but the overall prognosis remains poor [24][25] - The NCCN and CSCO guidelines recommend various treatment options, including the recent inclusion of Tarlatamab as a preferred second-line treatment [28][29] 3. Research and Development Focus - ADCs are rapidly advancing in the SCLC field, targeting multiple hot spots such as B7-H3, DLL3, and TROP-2, with no ADC products currently approved for SCLC [37][38] - DLL3 TCEs, particularly Tarlatamab, have shown promising early data and are expected to reshape the treatment landscape for SCLC [30][31] - Next-generation IO therapies are being developed to challenge the current PD-L1 standard in first-line SCLC treatment [8][36] 4. Investment Recommendations - The report suggests that companies with strong pipelines in the SCLC space, such as Zai Lab, Zai Lab-U, Innovent Biologics, and others, are likely to benefit from the anticipated growth in the market as new data emerges [9]

Group 1 - The Shanghai 50 Index (000016) increased by 0.46% as of May 12, 2025, with notable gains from China Shipbuilding (up 9.05%) and other companies like Haier Smart Home and Longi Green Energy [2] - The Shanghai 50 ETF (510050) rose by 0.58%, marking its fifth consecutive increase, with a management fee of 0.15% and a custody fee of 0.05%, the lowest among comparable funds [2] - As of April 30, 2025, the top ten weighted stocks in the Shanghai 50 Index included Kweichow Moutai, Ping An Insurance, and China Merchants Bank, with Kweichow Moutai holding the highest weight at 12.31% [4] Group 2 - Recent financial policies from the People's Bank of China, financial regulatory authorities, and the China Securities Regulatory Commission aim to stabilize the market and expectations, with April's import and export data showing strong resilience [4] - The release of liquidity and a decrease in financing costs are expected to directly benefit the real economy, with a rebound in social financing growth anticipated in the second quarter, particularly benefiting infrastructure and manufacturing investments [5] - The overall outlook for the Chinese economy remains positive, characterized by stability, advantages, resilience, and potential, suggesting a favorable development trend for the capital market with sustained inflows of long-term funds [5]

Summary of the Conference Call Industry Focus - The report focuses on the pharmaceutical industry, specifically highlighting innovative drugs and contract research organizations (CXO) Core Insights and Arguments - Continuous recommendation of innovative drugs with positive growth outlook, including: - 恒瑞医药 (Hengrui Medicine) - 华东医药 (East China Pharmaceutical) - 翰森制药 (Hansoh Pharmaceutical) - 贝达药业 (Betta Pharmaceuticals) - 信立泰 (Sinopharm) - 科伦药业 (Kelun Pharmaceutical) - 百利天恒 (Baili Tianheng) - 荣昌生物 (Rongchang Biopharmaceutical) - 科伦博泰生物 (Kelun Biotech) - 石药集团 (Shijiazhuang Pharmaceutical Group) [1][1][1] - Recommendation of CXOs showing signs of profit growth turning points, including: - 药明生物 (WuXi Biologics) - 药明康德 (WuXi AppTec) [1][1] - Positive outlook on domestic replacement of innovative medical devices, specifically: - 惠泰医疗 (Huitai Medical) [1] - Anticipation of recovery in consumer healthcare, particularly: - 爱尔眼科 (Aier Eye Hospital) [1] Other Important Points - The report emphasizes the ongoing trend of recommending companies that are positioned well within the pharmaceutical sector, particularly those that are expected to benefit from market dynamics and growth opportunities - The focus on innovative drugs and CXOs indicates a strategic approach to capitalize on emerging trends in the healthcare market - The mention of domestic replacements in medical devices suggests a shift towards local production and innovation, which could impact market competition and supply chains - The recovery in consumer healthcare points to potential growth areas as the market stabilizes post-pandemic

Market Performance - The market rebounded last week, with the China Securities Index rising by 1.99% to 1650.47 points [1][2] - The Shanghai Composite Index increased by 1.92%, the Shenzhen Component Index by 2.29%, and the ChiNext Index by 3.27% [2] Strong Stock Performances - Notable strong performers included: - Zhongji Xuchuang (300308) up by 13.55% - Shanghai Jahwa (600315) up by 9.31% - AVIC Shenyang Aircraft (600760) up by 8.25% - CATL (300750) up by 7.24% - Beitaini (300957) up by 6.01% [2] - Other stocks such as Hisense Home Appliances (000921), EVE Energy (300014), and Stone Technology saw gains exceeding 5% [2] Year-to-Date Stock Performance - Since the beginning of 2025, Shanghai Jahwa has surged by 51.39%, leading the gains [3] - Marumi Bio (603983) follows with a 50.59% increase, while Xintai (002294) and Anji Technology have both risen over 30% [3] Market Outlook - Positive factors are emerging as the market stabilizes, with expectations for gradual recovery in investor sentiment and stock performance [4] - The domestic economy is on a steady recovery path, supported by ongoing policy efforts [4] - The current A-share market is viewed as being in a high cost-performance zone, indicating medium to long-term investment value [4] - However, short-term market movements may remain volatile unless strong driving factors emerge [4]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of May 9, 2025, the latest net value of the fund is 2.5040 yuan, with a growth of 0.72%. The fund's return over the past month is 5.17%, ranking 504 out of 783 in its category; over the past three months, the return is 9.06%, ranking 88 out of 778; and year-to-date, the return is 9.87%, ranking 103 out of 773 [1] - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Mindray Medical (2.80%) [1] Group 2 - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan. The fund managers are Zhao Bei and Ding Yang [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014, while Ding Yang joined the company in 2017 and currently serves as a fund manager [2]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-076 注射用SHR-A1904为公司自主研发且具有知识产权的靶向Claudin18.2的抗 体药物偶联物（ADC），其有效载荷是拓扑异构酶抑制剂（TOPOi）。Claudin 蛋 白是一种紧密连接蛋白（TJ）的主要成分，维持 TJ 的各种功能，保持细胞内环 境的稳定。Claudin18.2 是一种高特异性的细胞表面分子，正常细胞中仅在有分 化的胃黏膜上皮细胞表达，而在胃癌、胰腺癌、食管癌等瘤种上高表达。截至目 前，注射用 SHR-A1904 相关项目累计研发投入约 12,225 万元。 注射用 SHR-A2009 是一款以 HER3 为靶点的抗体药物偶联物，可特异性结合 肿瘤细胞表面上的 HER3，进而被内吞至细胞内并转运至溶酶体中，水解释放游 离毒素，杀伤肿瘤细胞。全球尚未有同类药物获批上市。截至目前，注射用 SHR-A2009 相关项目累计研发投入约 12,275 万元。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司上海盛迪医药 有限公司、苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司收到国家药品监 督管理局（以下简称"国 ...

一、药品的基本情况 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-075 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签 发关于 SHR-1316(sc)注射液的《药物临床试验批准通知书》，将于近期开展临 床试验。现将相关情况公告如下： SHR-1316(sc)注射液为是公司自主研发的人源化抗 PD-L1 单克隆抗体皮下 制剂，能通过特异性结合 PD-L1 分子从而阻断导致肿瘤免疫耐受的 PD-1/PD-L1 通路，重新激活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝 利单抗注射液（静脉制剂）已于 2023 年 3 月获批上市，获批的适应症为与卡铂 和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。抗 PD-L1 单克隆抗体皮 下制剂同类产品 atezolizumab（商品名：Tecentri ...